Brought to you by 
ImmunoGen and Aventis develop anticancer drugs; Sanofi and ImmunoGen later amend
05 Oct 2021
Executive Summary
ImmunoGen's (cancer therapeutics) expertise in antibodies and Aventis's oncology product development experience will be combined in a three-year collaboration to discover, develop, and market antibody-based cancer treatments. Both partners will provide targets.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ImmunoGen and Aventis develop anticancer drugs; Sanofi and ImmunoGen later amend
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice